WASHINGTON, Dec. 17 /PRNewswire-USNewswire/ -- The Advanced Medical Technology Association (AdvaMed) announced today that it has established a new division – AdvaMed Dx – to focus solely on issues facing companies that manufacture in vitro diagnostic technologies. The division will function as an association within an association, while still having access to, and support from, the broader resources offered by AdvaMed.
"In vitro diagnostics exemplify the promise of better patient care in this exciting era of the life sciences. Having an advocacy organization that solely focuses on the unique regulatory, reimbursement and other policy interests of in vitro diagnostics companies will help this vitally important sector continue to grow and thrive, helping patients better detect and fight disease," said Stephen J. Ubl, president and CEO of AdvaMed.
AdvaMed Dx will be governed by an 18-member Board of Directors and an 8-member Executive Committee, comprised of CEOs from in vitro diagnostics companies. The Board of Directors will be chaired by Scott Garrett, Beckman Coulter's chairman, president and chief executive officer. Full-time staff will include an executive director and a director of communications that will be located in AdvaMed's offices and have access to the full complement of AdvaMed's policy expertise and other resources.
"There is no other organization in the U.S. that is focused solely on advancing the policy priorities of in vitro diagnostics companies, and I believe AdvaMed Dx offers an exciting opportunity for the diagnostics industry to strengthen its advocacy impact both domestically and abroad," said Scott Garrett.
Some of the issues of particular importance that AdvaMed Dx will focus on include establishment of a modernized risk-based approach to the regulation of in vitro diagnostics to support timely patient access to safe and effective tests. It will also focus on reforming the antiquated Medicare payment system for clinical laboratory diagnostic tests to fully recognize the value of new tests, especially the new generation of molecular diagnostic tests.
AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. Our members produce nearly 90 percent of the health care technology purchased annually in the United States and more than 50 percent purchased annually around the world. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit www.advamed.org.
SOURCE Advanced Medical Technology Association (AdvaMed)
Advertisement
"In vitro diagnostics exemplify the promise of better patient care in this exciting era of the life sciences. Having an advocacy organization that solely focuses on the unique regulatory, reimbursement and other policy interests of in vitro diagnostics companies will help this vitally important sector continue to grow and thrive, helping patients better detect and fight disease," said Stephen J. Ubl, president and CEO of AdvaMed.
Advertisement
AdvaMed Dx will be governed by an 18-member Board of Directors and an 8-member Executive Committee, comprised of CEOs from in vitro diagnostics companies. The Board of Directors will be chaired by Scott Garrett, Beckman Coulter's chairman, president and chief executive officer. Full-time staff will include an executive director and a director of communications that will be located in AdvaMed's offices and have access to the full complement of AdvaMed's policy expertise and other resources.
"There is no other organization in the U.S. that is focused solely on advancing the policy priorities of in vitro diagnostics companies, and I believe AdvaMed Dx offers an exciting opportunity for the diagnostics industry to strengthen its advocacy impact both domestically and abroad," said Scott Garrett.
Some of the issues of particular importance that AdvaMed Dx will focus on include establishment of a modernized risk-based approach to the regulation of in vitro diagnostics to support timely patient access to safe and effective tests. It will also focus on reforming the antiquated Medicare payment system for clinical laboratory diagnostic tests to fully recognize the value of new tests, especially the new generation of molecular diagnostic tests.
AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. Our members produce nearly 90 percent of the health care technology purchased annually in the United States and more than 50 percent purchased annually around the world. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit www.advamed.org.
SOURCE Advanced Medical Technology Association (AdvaMed)
